Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors

ClinicalTrials.gov ID: NCT06963281

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT06963281. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 5:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Multicenter, Open-label Study of IBI3020 Treatment in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main purpose of this study is to evaluate the safety and tolerability of IBI3020 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RP2D) of IBI3020.

Study identification

NCT ID: NCT06963281
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Fortvita Biologics (USA)Inc.; Industry
Enrollment: 285 participants

Conditions and interventions

Conditions

Solid Tumors

Interventions

IBI3020 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 29, 2025 (Actual)
Primary completion: Dec 31, 2027 (Estimated)
Completion: Mar 31, 2028 (Estimated)
Last update posted: Sep 25, 2026

2025 – 2028

United States locations

U.S. sites: 6
U.S. states: 5
U.S. cities: 6

Facility	City	State	ZIP	Site status
Mayo Clinic - Arizona	Phoenix	Arizona	85054	Recruiting
Mayo Clinic - Florida	Jacksonville	Florida	32224	Recruiting
Mayo Clinic - Rochester	Rochester	Minnesota	55905	Recruiting
Montefiore Cancer Center	New York	New York	10461	Recruiting
NEXT Houston	Houston	Texas	77054	Recruiting
NEXT Dallas	Irving	Texas	75039	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06963281, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 25, 2026 · Synced Nov 14, 2026